Rhea-AI Summary
Merck KGaA, Darmstadt, Germany, released topline results from the Phase II INTR@PID BTC 047 study of bintrafusp alfa in second-line treatment for patients with locally advanced or metastatic biliary tract cancer (BTC). The study involved 159 patients and showed an objective response rate (ORR) of 10.1%, which did not meet the regulatory threshold for submission. Despite the results, bintrafusp alfa's single-agent efficacy offers insights for future studies. An ongoing Phase II/III trial is assessing bintrafusp alfa combined with chemotherapy for BTC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
FAQ
What is the current stock price of MERCK KGAA (MKGAF)?
MERCK KGAA (MKGAF) last closed at $161.75.
What is the market cap of MERCK KGAA (MKGAF)?
The market cap of MERCK KGAA (MKGAF) is approximately $68.6B.